10 research outputs found

    Эффективность терапии Беродуалом Н с помощью малых спейсеров при обострении обструктивных болезней легких

    Get PDF
    The randomized controlled single hospital centre study assessed the efficacy of therapy with Berodual N (fenoterol / ipratropium) delivered by means of small spacers in patients with acute exacerbations of obstructive pulmonary diseases. Inclusion criteria were acute exacerbation of COPD or asthma, age 18–75 yrs, FEV1 30–60 %, no need for respiratory support. 61 patients with COPD or asthma (M : F = 37 : 24, mean age 59 ± 8 yrs; FEV1 — 40 ± 11 %, SpO2 = 94 ± 2 %) were randomized to Berodual N 2 inhalations via MDI (n = 31) or Berodual N 2 inhalations via spacer-MDI (n = 30). Therapy with Berodual N in both groups of patients led to statistically significant improvement in FEV1, FVC and IC, and to decrease in respiratory rate and dispnea. Therapy with Berodual N via spacer-MDI resulted in more significant improvement of FVC and IC (difference between groups after 0.5 and 1 h after inhalation: р < 0.05). Dyspnea score also improved more significantly in patients received Berodual N via spacer-MDI (difference between groups after 0.5 and 1 h after inhalation: р < 0.05). The incidence of adverse events was similar between the groups. Conclusion: in patients with acute exacerbations of obstructive pulmonary diseases therapy with Berodual N by means of small spacers and MDI is more effective in comparison with MDI only.Нами проведено рандомизированное контролируемое одноцентровое исследование по оценке эффективности терапии комбинированным бронхорасширяющим препаратом Беродуалом Н (фенотерол / ипратропиум) со спейсером малого объема у больных с обострениями обструктивных болезней легких. Критерии включения больных: обострение ХОБЛ или астмы, возраст — 18–75 лет, ОФВ1 — 30–60 %, отсутствие потребности в респираторной поддержке. В исследование были включены 61 больной ХОБЛ и астмой (M : Ж = 37 : 24, средний возраст — 59 ± 8 лет; ОФВ1 — 40 ± 11 %, SpO2 — 94 ± 2 %), больные были методом рандомизации разделены на 2 группы: терапия Беродуалом Н 2 вдоха через ДАИ (n = 31) и терапия Беродуалом Н 2 вдоха через спейсер-ДАИ (n = 30). Терапия Беродуалом Н в обеих группах больных привела к достоверному улучшению ОФВ1, ФЖЕЛ и Евд, снижению ЧДД и уменьшению диспное. Терапия Беродуалом Н через спейсер#ДАИ по сравнению ингаляцией через ДАИ привела к более выраженному улучшению параметров ФЖЕЛ и Евд (различия через 0,5 и 1 ч, р < 0,05). Уменьшение диспное также было более выражено в те же сроки в группе больных, использовавших спейсер-ДАИ (p < 0,05). Частота развития побочных эффектов оказалась сходной в обеих группах. Выводы: у больных с обострениями обструктивных болезней легких терапия Беродуалом Н при помощи спейсера малого объема более эффективна по сравнению с использованием ДАИ

    Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

    No full text
    WOS: 000468732700018PubMed ID: 31054483Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients. Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT. Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes. Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient.ESC - EORP; AmgenAmgen; Eli LillyEli Lilly; PfizerPfizer; SanofiSanofi-Aventis; Ferrer; Novo NordiskNovo NordiskThe EUROASPIRE V survey was carried out under the auspices of the ESC - EORP. Since the start of EORP, the following companies have supported the programme: Amgen, Eli Lilly, Pfizer, Sanofi, Ferrer and Novo Nordisk. The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript

    Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry.

    No full text

    Presentation, care and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology.

    No full text

    Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

    No full text
    Aims The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. Methods and results Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (inhospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, prehospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. Conclusion The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality

    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

    No full text
    BACKGROUND: Metoprolol can improve haemodynamics in chronic heart failure, but survival benefit has not been proven. We investigated whether metoprolol controlled release/extended release (CR/XL) once daily, in addition to standard therapy, would lower mortality in patients with decreased ejection fraction and symptoms of heart failure. METHODS: We enrolled 3991 patients with chronic heart failure in New York Heart Association (NYHA) functional class II-IV and with ejection fraction of 0.40 or less, stabilised with optimum standard therapy, in a double-blind randomised controlled study. Randomisation was preceded by a 2-week single-blind placebo run-in period. 1990 patients were randomly assigned metoprolol CR/XL 12.5 mg (NYHA III-IV) or 25.0 mg once daily (NYHA II) and 2001 were assigned placebo. The target dose was 200 mg once daily and doses were up-titrated over 8 weeks. Our primary endpoint was all-cause mortality, analysed by intention to treat. FINDINGS: The study was stopped early on the recommendation of the independent safety committee. Mean follow-up time was 1 year. All-cause mortality was lower in the metoprolol CR/XL group than in the placebo group (145 [7.2%, per patient-year of follow-up]) vs 217 deaths [11.0%], relative risk 0.66 [95% CI 0.53-0.81]; p=0.00009 or adjusted for interim analyses p=0.0062). There were fewer sudden deaths in the metoprolol CR/XL group than in the placebo group (79 vs 132, 0.59 [0.45-0.78]; p=0.0002) and deaths from worsening heart failure (30 vs 58, 0.51 [0.33-0.79]; p=0.0023). INTERPRETATION: Metoprolol CR/XL once daily in addition to optimum standard therapy improved survival. The drug was well tolerated

    Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

    No full text
    Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients. Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT. Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8\% of the patients and had been started or increased in intensity in 11.7\%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8\% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes. Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient

    Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

    No full text
    corecore